MADCAM1 and inflammatory bowel disease: Our data confirm previous studies suggesting that mechanisms other than blockade of the α4β7/MAdCAM-1 interaction of T cells might be responsible for the amelioration of symptoms in patients with IBD and the beneficial effects of vedolizumab in respect to viral control seen in rhesus macaques infected with SIV.